Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT05024045 | Study of Oral LOXO-338 in Patients With Advanced Blood Cancers | PHASE1 | ACTIVE NOT_RECRUITING | 316 | — | — | Sep 30, 2021 | Jun 1, 2026 | Mar 3, 2026 | 23 | United States, France +2 |
Measured by the number of patients with dose-limiting toxicities (DLTs)
Measured by the appropriate disease specified response criteria as appropriate to tumor type
Measured by the number of patients with dose-limiting toxicities (DLTs)
| Arm | Type | Description |
|---|---|---|
| LOXO-338 (Monotherapy) | EXPERIMENTAL | LOXO-338 administered orally. |
| LOXO-338 + Pirtobrutinib (Combination) | EXPERIMENTAL | LOXO-338 administered orally in combination with pirtobrutinib |
| Name | Type | Description |
|---|---|---|
| LOXO-338 | DRUG | Oral |
| Pirtobrutinib | DRUG | Oral |
Inclusion Criteria: * B-cell malignancy. * Patients must have received prior therapy. * Patients must have an objective indication for therapy. * Eastern Cooperative Oncology Group performance status (ECOG PS) of 0-1. * Anticipated life expectancy of greater than or equal to (≥) 12 weeks. * Adequat...